Literature DB >> 22300845

Relationships between lumbar bone mineral density and biochemical parameters in phenylketonuria patients.

Martijn J de Groot1, Marieke Hoeksma, Margreet van Rijn, Riemer H J A Slart, Francjan J van Spronsen.   

Abstract

BACKGROUND: The etiology of reduced bone mineral density (BMD) in phenylketonuria (PKU) is unknown. Reduced BMD may be inherent to PKU and/or secondary to its dietary treatment.
MATERIALS AND METHODS: Lumbar BMD was measured by dual-energy X-ray absorptiometry in 53 early and continuously treated PKU patients (median age 16, range 2-35 years). First, Z-scores of BMD were correlated to age group, clinical severity of PKU, mean phenylalanine (Phe) concentration and Phe variation in the year prior to DXA scanning, as well as to blood vitamin, mineral, and alkaline phosphatase concentrations. Second, parameters were compared between subjects with reduced BMD (Z-score<-2 SD) and subjects with normal BMD.
RESULTS: BMD was significantly reduced in our cohort (p=0.000). Z-scores of BMD were neither significantly correlated to age group, nor clinical severity of PKU. Both mean Phe concentration and Phe variation in the year prior to DXA scanning did not significantly correlate with Z-scores of BMD. Higher blood calcium concentrations were significantly associated with lower BMD (r(2)=-0.485, p=0.004). Other biochemical parameters, including vitamin B12 availability markers, did not show significant correlations with Z-score of BMD. Subjects with reduced BMD had significantly higher blood phosphorus concentrations than subjects with normal BMD (p=0.009). No other significant differences were found between both BMD groups.
CONCLUSION: Reduced BMD in PKU is present from early age onward and does not progress with age. Therefore, BMD deserves attention from early age onward in PKU patients. Our findings are consistent with increased bone turnover in PKU. It remains unclear whether reduced BMD is inherent to PKU and/or secondary to its dietary treatment. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300845     DOI: 10.1016/j.ymgme.2012.01.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  17 in total

1.  Analysis of the functional muscle-bone unit of the forearm in patients with phenylketonuria by peripheral quantitative computed tomography.

Authors:  Daniela Choukair; Carolin Kneppo; Reinhard Feneberg; Eckhard Schönau; Martin Lindner; Stefan Kölker; Georg F Hoffmann; Burkhard Tönshoff
Journal:  J Inherit Metab Dis       Date:  2016-11-22       Impact factor: 4.982

2.  A New View of Bone Loss in Phenylketonuria.

Authors:  Steven F Dobrowolski; Irina L Tourkova; Cayla R Sudano; Quitterie C Larrouture; Harry C Blair
Journal:  Organogenesis       Date:  2021-08-25       Impact factor: 2.316

Review 3.  A systematic review of bone mineral density and fractures in phenylketonuria.

Authors:  Karen E Hansen; Denise Ney
Journal:  J Inherit Metab Dis       Date:  2014-07-09       Impact factor: 4.982

4.  Modeling correlates of low bone mineral density in patients with phenylalanine hydroxylase deficiency.

Authors:  Kathryn E Coakley; Teresa D Douglas; Michael Goodman; Usha Ramakrishnan; Steven F Dobrowolski; Rani H Singh
Journal:  J Inherit Metab Dis       Date:  2016-02-16       Impact factor: 4.982

Review 5.  Advances in the nutritional and pharmacological management of phenylketonuria.

Authors:  Denise M Ney; Robert D Blank; Karen E Hansen
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2014-01       Impact factor: 4.294

6.  Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.

Authors:  Patrick Solverson; Sangita G Murali; Suzanne J Litscher; Robert D Blank; Denise M Ney
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

7.  Relationship between Biochemical Bone Markers and Bone Mineral Density in Patients with Phenylketonuria under Restricted Diet.

Authors:  Hala M Koura; Sherif M Zaki; Nagwa A Ismail; Emad E Salama; Dalia H El Lebedy; Laila K Effat
Journal:  Iran J Pediatr       Date:  2013-12-31       Impact factor: 0.364

Review 8.  Bone health in phenylketonuria: a systematic review and meta-analysis.

Authors:  Serwet Demirdas; Katie E Coakley; Peter H Bisschop; Carla E M Hollak; Annet M Bosch; Rani H Singh
Journal:  Orphanet J Rare Dis       Date:  2015-02-15       Impact factor: 4.123

9.  Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial.

Authors:  Denise M Ney; Bridget M Stroup; Murray K Clayton; Sangita G Murali; Gregory M Rice; Frances Rohr; Harvey L Levy
Journal:  Am J Clin Nutr       Date:  2016-07-13       Impact factor: 7.045

10.  Development of newborn screening connect (NBS connect): a self-reported patient registry and its role in improvement of care for patients with inherited metabolic disorders.

Authors:  Yetsa Osara; Kathryn Coakley; Aishwarya Devarajan; Rani H Singh
Journal:  Orphanet J Rare Dis       Date:  2017-07-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.